Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
26
08
2022
received:
11
05
2022
accepted:
29
08
2022
pubmed:
3
9
2022
medline:
19
11
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Transverse myelitis (TM) has recently been associated by health authorities with Ad26.COV2.S (Janssen/Johnson & Johnson), one of the 5 US Food and Drug Administration (FDA) or European Medicines Agency (EMA) labeled severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. It is unknown whether a similar association exists for the other FDA or EMA labeled SARS-CoV-2 vaccines (BNT162b2 [Pfizer/BioNTech], mRNA-1273 [Moderna], ChAdOx1nCov-19 [Oxford-AstraZeneca], and NVX-CoV2373 [Novavax]). This study aimed to evaluate the association between SARS-CoV-2 vaccine class and TM. This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from VigiBase, the World Health Organization's pharmacovigilance database. We first conducted a disproportionality analysis with the information component (IC) using the reports of TM that occurred within 28 days following exposure to the FDA or EMA labeled SARS-CoV-2 vaccines, from December 1, 2020 (first adverse event related to a SARS-CoV-2 vaccine) to March 27, 2022. Second, we analyzed the clinical features of SARS-CoV-2 vaccine-associated TM cases reported in VigiBase. TM was significantly associated both with the messenger ribonucleic acid (mRNA)-based (n = 364; IC Findings from this observational, cross-sectional pharmacovigilance study showed that mRNA-based and vector-based FDA/EMA labeled SARS-CoV-2 vaccines can be associated with TM. However, because TM remains a rare event, with a previously reported rate of 0.28 cases per 1 million vaccine doses, the risk-benefit ratio in favor of vaccination against SARS-CoV-2 virus remains unchallenged. Rather, this study suggests that clinicians should consider the diagnosis of TM in patients presenting with early signs of spinal cord dysfunction after SARS-CoV-2 vaccination. ANN NEUROL 2022;92:1080-1089.
Sections du résumé
BACKGROUND
Transverse myelitis (TM) has recently been associated by health authorities with Ad26.COV2.S (Janssen/Johnson & Johnson), one of the 5 US Food and Drug Administration (FDA) or European Medicines Agency (EMA) labeled severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. It is unknown whether a similar association exists for the other FDA or EMA labeled SARS-CoV-2 vaccines (BNT162b2 [Pfizer/BioNTech], mRNA-1273 [Moderna], ChAdOx1nCov-19 [Oxford-AstraZeneca], and NVX-CoV2373 [Novavax]). This study aimed to evaluate the association between SARS-CoV-2 vaccine class and TM.
METHODS
This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from VigiBase, the World Health Organization's pharmacovigilance database. We first conducted a disproportionality analysis with the information component (IC) using the reports of TM that occurred within 28 days following exposure to the FDA or EMA labeled SARS-CoV-2 vaccines, from December 1, 2020 (first adverse event related to a SARS-CoV-2 vaccine) to March 27, 2022. Second, we analyzed the clinical features of SARS-CoV-2 vaccine-associated TM cases reported in VigiBase.
RESULTS
TM was significantly associated both with the messenger ribonucleic acid (mRNA)-based (n = 364; IC
CONCLUSIONS
Findings from this observational, cross-sectional pharmacovigilance study showed that mRNA-based and vector-based FDA/EMA labeled SARS-CoV-2 vaccines can be associated with TM. However, because TM remains a rare event, with a previously reported rate of 0.28 cases per 1 million vaccine doses, the risk-benefit ratio in favor of vaccination against SARS-CoV-2 virus remains unchallenged. Rather, this study suggests that clinicians should consider the diagnosis of TM in patients presenting with early signs of spinal cord dysfunction after SARS-CoV-2 vaccination. ANN NEUROL 2022;92:1080-1089.
Identifiants
pubmed: 36054163
doi: 10.1002/ana.26494
pmc: PMC9538824
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
BNT162 Vaccine
0
COVID-19 Vaccines
0
NVX-CoV2373 adjuvated lipid nanoparticle
2SCD8Q63PF
RNA, Messenger
0
Viral Vaccines
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1089Informations de copyright
© 2022 American Neurological Association.
Références
Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59:499-505. https://doi.org/10.1212/wnl.59.4.499.
Román GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol 2021;12:653786. https://doi.org/10.3389/fimmu.2021.653786.
Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009;18:1198-1204. https://doi.org/10.1177/0961203309345730.
Research C for BE and Fluvirin. FDA. November 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/fluvirin. Accessed December 17, 2021.
Research C for BE and Fluarix Quadrivalent. FDA. June 2021. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/fluarix-quadrivalent. Accessed December 17, 2021.
Research C for BE and Fluarix. FDA. December 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/fluarix. Accessed December 17, 2021.
Research C for BE and Measles, Mumps and Rubella Virus Vaccine Live. FDA. December 2020. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/measles-mumps-and-rubella-virus-vaccine-live. Accessed December 17, 2021.
Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity-friends or foes? Trends Immunol 2009;30:409-414. https://doi.org/10.1016/j.it.2009.05.005.
Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J. 2004;6:430-432.
Baxter R, Lewis E, Goddard K, et al. Acute demyelinating events following vaccines: a case-centered analysis. Clin Infect Dis Off Publ Infect Dis Soc Am 2016;63:1456-1462. https://doi.org/10.1093/cid/ciw607.
Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 2021;27:1-10. https://doi.org/10.1038/s41591-021-01556-7.
EMA-6 October 2021 COVID-19 vaccine safety update-COVID-19 Vaccine JANSSEN. Available at: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf. Accessed October 2021.
Tan WY, Yusof Khan AHK, Mohd Yaakob MN, et al. Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report. BMC Neurol 2021;21:395. https://doi.org/10.1186/s12883-021-02427-x.
Tahir N, Koorapati G, Prasad S, et al. SARS-CoV-2 vaccination-induced transverse myelitis. Cureus 2021;13:e16624. https://doi.org/10.7759/cureus.16624.
Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol 2021;358:577606. https://doi.org/10.1016/j.jneuroim.2021.577606.
Notghi AA, Atley J, Silva M. Lessons of the month 1: longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clin Med Lond Engl 2021;21:e535-e538. https://doi.org/10.7861/clinmed.2021-0470.
Khan E, Shrestha AK, Colantonio MA, et al. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol 2021;269:1121-1132. https://doi.org/10.1007/s00415-021-10785-2.
Hsiao YT, Tsai MJ, Chen YH, Hsu CF. Acute transverse myelitis after COVID-19 vaccination. Med Kaunas Lith 2021;57:1010. https://doi.org/10.3390/medicina57101010.
Gao JJ, Tseng HP, Lin CL, et al. Acute transverse myelitis following COVID-19 vaccination. Vaccine 2021;9:1008. https://doi.org/10.3390/vaccines9091008.
Erdem NŞ, Demirci S, Özel T, et al. Acute transverse myelitis after inactivated COVID-19 vaccine. Ideggyogyaszati Szle 2021;74:273-276. https://doi.org/10.18071/isz.74.0273.
Malhotra HS, Gupta P, Prabhu V, et al. COVID-19 vaccination-associated myelitis. QJM Int J Med 2021;114:591-593. https://doi.org/10.1093/qjmed/hcab069.
Tregunno PM, Fink DB, Fernandez-Fernandez C, et al. Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf 2014;37:249-258. https://doi.org/10.1007/s40264-014-0146-y.
UMC | VigiBase. Available at: https://www.who-umc.org/vigibase/vigibase/. Accessed November 30, 2021.
Centre UM. VigiBase frequently asked questions. Available at: https://who-umc.org/vigibase/vigibase-faqs/. Accessed June 22, 2022.
Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother 2021;7:312-320. https://doi.org/10.1093/ehjcvp/pvaa037.
Dolladille C, Ederhy S, Ezine E, et al. Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study. Am J Hematol 2021;96:1101-1111. https://doi.org/10.1002/ajh.26259.
Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315-321. https://doi.org/10.1007/s002280050466.
Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig 2017;37:415-422. https://doi.org/10.1007/s40261-017-0503-6.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl 2021;397:99-111. https://doi.org/10.1016/S0140-6736(20)32661-1.
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187-2201. https://doi.org/10.1056/NEJMoa2101544.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. https://doi.org/10.1056/NEJMoa2035389.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. https://doi.org/10.1056/NEJMoa2034577.
Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15:586-594. https://doi.org/10.1038/cmi.2017.151.
Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res 2020;68:1-4. https://doi.org/10.1007/s12026-020-09152-6.
Li X, Ostropolets A, Makadia R, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ 2021;373:n1435. https://doi.org/10.1136/bmj.n1435.
Frontera JA, Tamborska AA, Doheim MF, et al. Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann Neurol 2022;91:756-771. https://doi.org/10.1002/ana.26339.
Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021;326:1-10. https://doi.org/10.1001/jama.2021.15072.
Commissioner O of the Comirnaty and Pfizer-BioNTech COVID-19 vaccine. FDA. February 2022. Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine. Accessed March 28, 2022.
Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021;5:947-953. https://doi.org/10.1038/s41562-021-01122-8.
Neha R, Subeesh V, Beulah E, et al. Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength. Hosp Pharm 2021;56:152-158. https://doi.org/10.1177/0018578719882323.